Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-03-15

FDA Approved: EDURANT PED — Original Application (Janssen Products, LP)

View source ↗

Summary

FDA approved EDURANT PED (rilpivirine hydrochloride) for HIV-1 infection in pediatric patients, establishing the original pediatric indication for this therapy.…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EDURANT PED (rilpivirine hydrochloride)

Snippet

ORIG AP for EDURANT PED (RILPIVIRINE HYDROCHLORIDE)